ACTIVITY INVITRO OF RIFABUTIN, FCE-22807, RIFAPENTINE, AND RIFAMPIN AGAINST MYCOBACTERIUM-MICROTI AND MYCOBACTERIUM-TUBERCULOSIS AND THEIR PENETRATION INTO MOUSE PERITONEAL-MACROPHAGES

被引:41
作者
DHILLON, J [1 ]
MITCHISON, DA [1 ]
机构
[1] ROYAL POSTGRAD MED SCH,DEPT BACTERIOL,DUCANE RD,LONDON W12 0NN,ENGLAND
来源
AMERICAN REVIEW OF RESPIRATORY DISEASE | 1992年 / 145卷 / 01期
关键词
D O I
10.1164/ajrccm/145.1.212
中图分类号
R56 [呼吸系及胸部疾病];
学科分类号
摘要
The activities of the rifamycins, rifabutin, FCE 22807, rifapentine, and rifampin, were studied within unstimulated peritoneal macrophages infected with Mycobacterium microti and in cultures of M. microti and M. tuberculosis in 7H-9 medium without Tween 80. In macrophage cultures, serial rifamycin concentrations were added after a 2.5 h phagocytosis period, and viable counts were done after incubation for 5 to 6 days. To ensure comparability with the dally drug replacements in the macrophage experiments, the period of exposure to serial rifamycin concentrations in 7H-9 medium was kept to only 3 days. The MICs of M. microti and M. tuberculosis were similar. The MICs of rifabutin and FCE 22807 were 2.5 times lower and that of rifapentine 1.7 times lower than the MIC of rifampin. None of the rifamycins were concentrated in macrophages, the MICs being higher in the macrophages than in vitro by a factor of 2-fold for rifabutin, 6.7-fold for rifampin, 20-fold for FCE 22807, and 26-fold for rifapentine.
引用
收藏
页码:212 / 214
页数:3
相关论文
共 14 条
[1]   EFFECTIVENESS OF OFLOXACIN AGAINST MYCOBACTERIUM-TUBERCULOSIS AND MYCOBACTERIUM-AVIUM, AND RIFAMPIN AGAINST M-TUBERCULOSIS IN CULTURED HUMAN MACROPHAGES [J].
CROWLE, AJ ;
ELKINS, N ;
MAY, MH .
AMERICAN REVIEW OF RESPIRATORY DISEASE, 1988, 137 (05) :1141-1146
[2]   LABORATORY EVALUATION OF A NEW LONG-ACTING 3-AZINOMETHYLRIFAMYCIN FCE 22250 [J].
DELLABRUNA, C ;
UNGHERI, D ;
SEBBEN, G ;
SANFILIPPO, A .
JOURNAL OF ANTIBIOTICS, 1985, 38 (06) :779-786
[3]  
DELLABRUNA C, 1983, J ANTIBIOT, V36, P1502
[4]   ACTIVITY AND PENETRATION OF ANTITUBERCULOSIS DRUGS IN MOUSE PERITONEAL-MACROPHAGES INFECTED WITH MYCOBACTERIUM-MICROTI OV254 [J].
DHILLON, J ;
MITCHISON, DA .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1989, 33 (08) :1255-1259
[5]   INVITRO ACTIVITY OF NEW RIFAMYCINS AGAINST RIFAMPICIN-RESISTANT MYCOBACTERIUM-TUBERCULOSIS AND MAIS-COMPLEX MYCOBACTERIA [J].
DICKINSON, JM ;
MITCHISON, DA .
TUBERCLE, 1987, 68 (03) :177-182
[6]   INVITRO OBSERVATIONS ON THE SUITABILITY OF NEW RIFAMYCINS FOR THE INTERMITTENT CHEMOTHERAPY OF TUBERCULOSIS [J].
DICKINSON, JM ;
MITCHISON, DA .
TUBERCLE, 1987, 68 (03) :183-193
[7]   INVITRO ACTIVITIES AGAINST MYCOBACTERIA OF 2 LONG-ACTING RIFAMYCINS, FCE22807 AND CGP40/469A (SPA-S-565) [J].
DICKINSON, JM ;
MITCHISON, DA .
TUBERCLE, 1990, 71 (02) :109-115
[8]  
FANFANI A, 1985, RIFABUTIN LM427 ANSA
[9]  
HAND WL, 1984, AM REV RESPIR DIS, V129, P933
[10]   RIFABUTINE - MINIMAL INHIBITORY AND BACTERICIDAL CONCENTRATIONS FOR MYCOBACTERIUM-TUBERCULOSIS [J].
HEIFETS, LB ;
LINDHOLMLEVY, PJ ;
ISEMAN, MD .
AMERICAN REVIEW OF RESPIRATORY DISEASE, 1988, 137 (03) :719-721